[Combination of transrectal 125I seeds implantation brachytherapy and intermittent hormonal therapy for locally advanced prostate cancer].
OBJECTIVE
To evaluate the clinical efficacy of transrectal 125 I seeds implantation brachytherapy (BT) combined with intermittent hormonal therapy (IHT) in the treatment of locally advanced prostate cancer.


METHODS
We treated 27 patients with locally advanced prostate cancer by transrectal 125I seeds implantation BT combined with IHT, and dynamically observed the changes in the PSA level, prostate volume, maximum urinary flow rate (Qmax) and International Prostate Symptoms Score (IPSS).


RESULTS
All the implantation procedures were completed smoothly, lasting 20 to 35 minutes, with 40 to 58 seeds implanted. At 6 months after implantation, the PSA level was < 0.2 microg/L in all the patients (< 0.1 microg/L in 19 cases), the prostate volume was significantly reduced (P < 0.05), and Qmax and IPSS remarkably improved (P < 0.05). At 3 years after implantation, 19 cases were in the first cycle and the other 8 in the third cycle of IHT, of which 2 progressed to androgen-independent prostate cancer, and another 2 developed early bone metastasis. The rates of 3-year biochemically and clinically progression-free survival were 70.3% and 85.2%, respectively, and the rate of therapeutic effectiveness was 92.6%. No severe complications occurred in any of the cases.


CONCLUSIONS
Transrectal 125I seeds implantation BT combined with IHT is a safe and minimally invasive procedure for locally advanced prostate cancer, which can effectively retard its clinical progression with no such complications as severe urethral, rectal or erectile dysfunction.
PLA Research Institute of Urology, Guangzhou General Hospital of Guangzhou Military Region, Guangzhou, Guangdong 510010, China. ahand@126.com
Hao-Ming
HM
Wu
Jun
J
Lü
Wei-Lie
WL
Hu
Jin-He
JH
Zhang
Wei
W
Wang
Yuan-Song
YS
Xiao
Nan-Xiong
NX
Wang
Jun-Wu
JW
Ran
Xiao-Dong
XD
Huang
D000368:Aged; D001918:Brachytherapy; D003131:Combined Modality Therapy; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms / Q000532:radiotherapy* / Q000628:therapy*; D016896:Treatment Outcome
D006728:Hormones; D007457:Iodine Radioisotopes